The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial

Richardson, H.; Johnston, D.; Pater, J.; Goss, P.

doi:10.3747/co.2007.117

Open AccessArticle

The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial

by

H. Richardson

¹,

D. Johnston

¹,

J. Pater

¹ and

P. Goss

^2,* on behalf of the MAP.3 Consortium

¹

National Cancer Institute of Canada Clinical Trials Group, Queen’s University, Kingston, ON, Canada

²

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

^*

Author to whom correspondence should be addressed.

Curr. Oncol. 2007, 14(3), 89-96; https://doi.org/10.3747/co.2007.117

Submission received: 1 March 2007 / Revised: 3 April 2007 / Accepted: 1 May 2007 / Published: 1 June 2007

Download

Abstract

Several large phase iii trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (AIS) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) has developed a randomized phase III study to determine the efficacy of an AI (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The NCIC CTG MAP.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the AIS, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene.

Keywords: aromatase inhibitors; breast cancer risk reduction; chemoprevention

Share and Cite

MDPI and ACS Style

Richardson, H.; Johnston, D.; Pater, J.; Goss, P., on behalf of the MAP.3 Consortium. The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial. Curr. Oncol. 2007, 14, 89-96. https://doi.org/10.3747/co.2007.117

AMA Style

Richardson H, Johnston D, Pater J, Goss P on behalf of the MAP.3 Consortium. The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial. Current Oncology. 2007; 14(3):89-96. https://doi.org/10.3747/co.2007.117

Chicago/Turabian Style

Richardson, H., D. Johnston, J. Pater, and P. Goss on behalf of the MAP.3 Consortium. 2007. "The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial" Current Oncology 14, no. 3: 89-96. https://doi.org/10.3747/co.2007.117

APA Style

Richardson, H., Johnston, D., Pater, J., & Goss, P., on behalf of the MAP.3 Consortium. (2007). The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial. Current Oncology, 14(3), 89-96. https://doi.org/10.3747/co.2007.117

Article Menu

The National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: An International Breast Cancer Prevention Trial

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI